Nothing Special   »   [go: up one dir, main page]

Carneiro et al., 2016 - Google Patents

Is personalized medicine here?

Carneiro et al., 2016

Document ID
12351370130352363729
Author
Carneiro B
Costa R
Taxter T
Chandra S
Chae Y
Cristofanilli M
Giles F
Publication year
Publication venue
Oncology

External Links

Snippet

Major technologic advances in genomics have made possible the identification of critical genetic alterations in cancer, which has led to a rapid paradigm shift in what is now considered personalized cancer treatment. This exponential growth in the understanding of …
Continue reading at go.gale.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Sartore-Bianchi et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Taber et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis
Berger et al. The emerging clinical relevance of genomics in cancer medicine
Rodrigues et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Senft et al. Precision oncology: the road ahead
Meric-Bernstam et al. A decision support framework for genomically informed investigational cancer therapy
Radovich et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
Collins et al. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics
Le Tourneau et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials
Roychowdhury et al. Translating cancer genomes and transcriptomes for precision oncology
Coyne et al. Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH
Kurnit et al. Precision oncology decision support: current approaches and strategies for the future
Ma et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer
Bryce et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery
Syn et al. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review
MacConaill et al. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges
Park et al. Next-generation sequencing in the clinic
Groisberg et al. The role of next-generation sequencing in sarcomas: evolution from light microscope to molecular microscope
Carneiro et al. Is personalized medicine here?
Hempel et al. Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients
Xue et al. Changing paradigm of cancer therapy: precision medicine by next-generation sequencing
Lee et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Sinn et al. TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: Next-generation sequencing results from the CONKO-001 trial
Weiss et al. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making
Edsjö et al. Precision cancer medicine: Concepts, current practice, and future developments